# FDA 483 - Dixon Investments Inc - March 22, 2019

Source: https://www.globalkeysolutions.net/records/483/dixon-investments-inc/a5d5d5be-99cc-4091-8d68-9db489700ed0

> FDA 483 for Dixon Investments Inc on March 22, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Dixon Investments Inc
- Inspection Date: 2019-03-22
- Product Type: drugs
- Office Name: Atlanta District Office
- Summary: Dixon Investments, Inc. DBA ARI, an OTC liquid and aerosol drug manufacturer in Orchard Hill, GA, was inspected by the FDA. The inspection revealed significant deficiencies in manufacturing process validation, quality control testing, discrepancy investigations, and stability testing. Several observations were repeat findings, indicating persistent issues with GMP compliance.

## Related Documents

- [WARNING_LETTER - 2025-03-11](https://www.globalkeysolutions.net/records/warning_letter/dixon-investments-inc/e32a11d5-1d68-4faf-815e-e68cab540db2)

## Related Officers

- [Susan O. Oladeji](https://www.globalkeysolutions.net/people/susan-o-oladeji/307277f8-7704-4ada-8d8d-d77118c6cb77)

Company: https://www.globalkeysolutions.net/companies/dixon-investments-inc/ce191609-e6f1-4391-8f04-21996703095d

Office: https://www.globalkeysolutions.net/offices/atlanta-district-office/7586d99a-288e-49d1-8c3d-d88b7354b7a7